Development of Future Medical Seeds via Innovation Eco-system

The development of support system for the innovation of preventive and therapeutic modalities (future-directed seeds) is still behind, which humpers clinical application of academia's discovery. Overseas spillage and development breakdown of promising seeds in turn slow down medical development and lead to an enormous economic loss. We, therefore, train such professionals as research doctors, URA, project managers, among others, by faculty members of the Center for Antibody and Vaccine Therapy with numerous achievements. This enhances the support system for translational research and clinical trials through professional cooperation. At the same time, we will further improve the efficiency of seed development by utilizing our outstanding AI / ICT environment, infrastructure and various biological sample banks. In addition, we will renovate our hospital to establish a future seed development base which can jointly be used by the industry, government and academia. As such, we will realize "advanced innovation ecosystem" to accelerate the development of future-directed seeds and create brand-new medical care, thereby contributing to the realization of a healthy society in the future.

- Institute of Medical Science, Advanced Clinical Research Center
- IMSUT Hospital
- Institute of Medical Science, International Research and Development Center for Mucosal Vaccine
- Institute of Medical Science, International Research Center for Infectious Diseases

- Azegami T, Yuki Y, Sawada S, Mejima M, Ishige K, Akiyoshi K, Itoh H, Kiyono H. Nanogel-based nasal ghrelin vaccine prevents obesity. Mucosal Immunol. 2017 Jan 25. Doi: 10.1038/mi.2016.137.
- Kunisawa J, Sugiura Y, Wake T, Nagatake T, Suzuki H, Nagasawa R, Shikata S, Honda K, Hashimoto E, Suzuki Y, Setou M, Suematsu M, Kiyono H.Mode of Bioenergetic Metabolism during B Cell Differentiation in the Intestine Determines the Distinct Requirement for Vitamin B1. Cell Rep. 2015 Oct 6;13(1):122-31.
- Takeyama N, Yuki Y, Tokuhara D, Oroku K, Mejima M, Kurokawa S, Kuroda M, Kodama T, Nagai S, Ueda S, Kiyono H. Oral rice-based vaccine induces passive and active immunity against enterotoxigenic E. coli-mediated diarrhea in pigs. Vaccine. 2015 Sep 22;33(39):5204-11.
- Li C, Hatta M, Burke DF, Ping J, Zhang Y, Ozawa M, Taft AS, Das SC, Hanson AP, Song J, Imai M, Wilker PR, Watanabe T, Watanabe S, Ito M, Iwatsuki-Horimoto K, Russell CA, James SL, Skepner E, Maher EA, Neumann G, Klimov A, Kelso A, McCauley J, Wang D, Shu Y, OdagiriT, Tashiro M, Xu X, Wentworth DE, Katz JM, Cox NJ, Smith DJ, Kawaoka Y. Selection of antigenically advanced variants of seasonal influenza viruses. Nat Microbiol 1:16058, 2016.
- Ping J, Lopes T.J.S, Nidom CA, Ghedin E, Macken CA, Fitch A, Imai M, Maher EA, Neumann G, Kawaoka Y. Development of high-yield influenza A virus vaccine viruses. Nat Commun 6:8148, 2015.
- Bornholdt ZA, Noda T, Abelson DM, Halfmann P, Wood MR, Kawaoka Y, Saphire EO. Structural rearrangement of Ebola virus VP40 begets multiple functions in the virus life cycle. Cell 154:763-774, 2013.
- Xiong X, Coombs PJ, Martin SR, Liu J, Xiao H, McCauley JW, Locher K, Walker PA, Collins PJ, Kawaoka Y, Skehel JJ, Gamblin SJ. Receptor binding by a ferret-transmissible H5 avian influenza virus. Nature 497:392-396, 2013.
- Miyoshi, S., Tezuka, T., Arimura, S., Tomono, T., Okada, T., and Yamanashi, Y. DOK7 gene therapy enhances motor activity and life span in ALS model mice. EMBO Mol. Med. Published online e201607298 (2017)
- Arimura, S., Okada, T., Tezuka, T., Chiyo, T., Kasahara, Y., Yoshimura, T., Motomura, M., Yoshida, N., Beeson, D., Takeda, S., and Yamanashi, Y. DOK7 gene therapy benefits mouse models of diseases characterized by defects in the neuromuscular junction. Science 345: 1505-1508 (2014)